Aliases & Classifications for Phobic Disorder

MalaCards integrated aliases for Phobic Disorder:

Name: Phobic Disorder 12 14
Phobic Anxiety Disorder 69

Classifications:



Summaries for Phobic Disorder

Disease Ontology : 12 An anxiety disorder where fear and anxiety are triggered by a specific stimulus or situation.

MalaCards based summary : Phobic Disorder, also known as phobic anxiety disorder, is related to social phobia and phobia, specific. An important gene associated with Phobic Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Cycloserine and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include brain, ovary and skin, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Phobic Disorder

Diseases related to Phobic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
id Related Disease Score Top Affiliating Genes
1 social phobia 11.5
2 phobia, specific 10.8
3 agoraphobia 10.8
4 paranoid personality disorder 10.6 HTR1A PIR
5 conjunctival pigmentation 10.6 MAOA SLC6A4
6 dissociative disorder 10.5 PIR SLC6A4
7 ornithosis 10.5 MAOA SLC6A4
8 conjunctival degeneration 10.5 HTR1A SLC6A4
9 anodontia 10.5 HTR1A SLC6A4
10 pyromania 10.5 MAOA SLC6A4
11 pompholyx 10.5 HTR1A SLC6A4
12 luxation of globe 10.4 HTR1A SLC6A4
13 neurogenic bladder 10.4 MAOA PIR SLC6A4
14 tinea pedis 10.3 HTR1A MAOA SLC6A4
15 acquired aneurysmal subarachnoid hemorrhage 10.3 HTR1A MAOA SLC6A4
16 hypoglycemic coma 10.3 HTR1A MAOA SLC6A4
17 cyclotropia 10.3 COMT OPRK1
18 amyloidosis, finnish type 10.3 COMT MAOA
19 heroin dependence 10.2 MAOA OPRK1 SLC6A4
20 suppurative periapical periodontitis 10.2 OPRK1 SLC6A4
21 mandibular cancer 10.2 HTR1A SLC6A4
22 hypertrophy of breast 10.2 NBAS PIR
23 atrial fibrillation, familial, 10 10.1 HTR1A MAOA SLC6A4
24 hemorrhagic cystitis 10.1 COMT MAOA SLC6A4
25 tongue disease 10.1 COMT MAOA SLC6A4
26 intrahepatic gall duct cancer 10.1 COMT MAOA SLC6A4
27 pauci-immune glomerulonephritis with anca 10.1 COMT MAOA SLC6A4
28 carotid stenosis 10.1 COMT MAOA SLC6A4
29 anosognosia 10.1 COMT HTR1A SLC6A4
30 chagas disease 10.1 COMT MAOA SLC6A4
31 colon mucinous adenocarcinoma 10.1 COMT MAOA SLC6A4
32 hereditary multiple exostoses 10.1 COMT MAOA SLC6A4
33 primary angle-closure glaucoma 10.1 COMT HTR1A SLC6A4
34 acute female pelvic peritonitis 10.0 OPRK1 SLC6A4
35 chronic conjunctivitis 10.0 COMT HTR1A SLC6A4
36 ring chromosome 14 syndrome 10.0 COMT MAOA NBAS
37 postencephalitic parkinson disease 9.9 HTR1A MAOA RGS2 SLC6A4
38 bone fracture 9.9 COMT HTR1A SLC6A4
39 laryngeal adductor paralysis 9.9 HTR1A SLC6A4
40 renpenning syndrome 9.8 COMT HTR1A MAOA SLC6A4
41 chronic dacryoadenitis 9.8 COMT HTR1A MAOA SLC6A4
42 obsessive-compulsive personality disorder 9.8 COMT HTR1A MAOA SLC6A4
43 keratosis 9.8 COMT HTR1A MAOA SLC6A4
44 cecal benign neoplasm 9.8 COMT HTR1A MAOA SLC6A4
45 vallecula cancer 9.8 COMT HTR1A MAOA SLC6A4
46 sexual disorder 9.8 COMT MAOA SLC6A4
47 personality disorder 9.8 COMT HTR1A MAOA SLC6A4
48 aicardi-goutieres syndrome 2 9.8 COMT HTR1A MAOA SLC6A4
49 partial motor epilepsy 9.8 COMT HTR1A MAOA SLC6A4
50 albinism, oculocutaneous, type v 9.8 COMT HTR1A MAOA SLC6A4

Graphical network of the top 20 diseases related to Phobic Disorder:



Diseases related to Phobic Disorder

Symptoms & Phenotypes for Phobic Disorder

MGI Mouse Phenotypes related to Phobic Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 COMT GLRB HTR1A MAOA OPRK1 RGS2
2 cardiovascular system MP:0005385 9.5 COMT GLRB HTR1A MAOA PTK7 RGS2
3 nervous system MP:0003631 9.23 COMT GLRB HTR1A MAOA OPRK1 PTK7

Drugs & Therapeutics for Phobic Disorder

Drugs for Phobic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cycloserine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68-41-7 401 6234
2
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
3
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
4
Ethanol Approved Phase 4,Phase 2 64-17-5 702
5
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
6
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
7
Sertraline Approved Phase 4,Phase 3,Phase 2 79617-96-2 68617
8
Tiagabine Approved Phase 4 115103-54-3 60648
9 Piracetam Approved Phase 4,Phase 2 7491-74-9
10
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
11
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
12
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
13
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3 525-66-6 4946
14
Lidocaine Approved, Vet_approved Phase 4,Phase 1,Phase 2 137-58-6 3676
15
Topiramate Approved Phase 4 97240-79-4 5284627
16
Acetylcholine Approved Phase 4 51-84-3 187
17
Vortioxetine Approved Phase 4 508233-74-7 9966051
18
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
19 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
20 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
22 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
23 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 3,Phase 1
24 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
25 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
26
Serotonin Phase 4,Phase 2,Phase 3,Phase 1 50-67-9 5202
27 Serotonin Agents Phase 4,Phase 2,Phase 3,Phase 1
28 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
29 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Renal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Phase 1
36 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
37 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1
38 Cholinergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
39 Muscarinic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
40 Parasympatholytics Phase 4,Phase 2,Phase 3,Phase 1
41 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
42 Serotonin 5-HT1 Receptor Agonists Phase 4
43 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
44 Quetiapine Fumarate Phase 4,Phase 3,Phase 2,Early Phase 1 111974-72-2
45 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
47 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
48 Anticonvulsants Phase 4,Phase 2,Phase 3
49 GABA Agents Phase 4,Phase 2,Phase 1
50 GABA Modulators Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 327)

id Name Status NCT ID Phase Drugs
1 The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment Completed NCT00407199 Phase 4 quetiapine
2 RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo Completed NCT00184106 Phase 4 Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
3 D-Cycloserine Enhancement of Exposure in Social Phobia Completed NCT00633984 Phase 4 D-Cycloserine;Placebo
4 Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder Completed NCT00282828 Phase 4 Sertraline;Venlafaxine;Placebo;Clonazepam
5 Nefazodone in the Treatment of Social Phobia Completed NCT00231348 Phase 4 Nefazodone
6 Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents Completed NCT01160588 Phase 4 Sertraline
7 Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder Completed NCT00872131 Phase 4 Sertraline
8 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder Completed NCT01316302 Phase 4 Pristiq;Placebo
9 Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder Completed NCT00208741 Phase 4 Gabitril
10 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4 Levetiracetam
11 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
12 Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder Completed NCT00767871 Phase 4 Lexapro
13 Escitalopram in Patients With Social Anxiety Disorder Completed NCT00902226 Phase 4 Escitalopram
14 Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults Completed NCT01224067 Phase 4 Quetiapine
15 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Completed NCT00177008 Phase 4 Aripiprazole
16 Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder Completed NCT00190879 Phase 4 Atomoxetine hydrochloride;placebo
17 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4 Psychotropic medication optimization
18 Acamprosate in Alcoholics With Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
19 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
20 Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP) Recruiting NCT00182455 Phase 4 Topiramate;Placebo
21 Brief Intervention to Reduce Fear of Public Speaking Recruiting NCT02790736 Phase 4 propranolol;placebo
22 A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder Recruiting NCT03078270 Phase 4 botulinum toxin A
23 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Active, not recruiting NCT00182533 Phase 4 Sertraline;Placebo
24 Comparison of Routine IM Influenza Immunization and Administration by Jet-injector in Healthy Young Adults Active, not recruiting NCT03150537 Phase 4
25 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Active, not recruiting NCT02294305 Phase 4 Vortioxetine;Placebo
26 Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias Terminated NCT01623583 Phase 4
27 Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice Unknown status NCT01388231 Phase 2, Phase 3
28 Study of Escitalopram in the Treatment of Specific Phobia Completed NCT00121069 Phase 2, Phase 3 Escitalopram
29 Treatment of Childhood Social Phobia Completed NCT00043537 Phase 3 Fluoxetine;Pill Placebo
30 Residential Cognitive and Interpersonal Therapy for Social Phobia Completed NCT00326430 Phase 2, Phase 3
31 A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy Completed NCT00564967 Phase 3
32 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
33 Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia Completed NCT00515879 Phase 3 D-cycloserine;Placebo
34 Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety Completed NCT00958880 Phase 3 Yohimbine Hydrochloride;Sugar Pill
35 Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants Completed NCT00734422 Phase 2, Phase 3
36 Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants Completed NCT02007694 Phase 2, Phase 3
37 Long-term Study Of Paroxetine in Women and Men Completed NCT00264654 Phase 3 BRL29060A;paroxetine hydrochloride hydrate
38 D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia Completed NCT01102803 Phase 3 D-Cycloserine;Placebo
39 Social Anxiety Disorder Study Of Paroxetine Completed NCT00318669 Phase 3 Paroxetine hydrochloride hydrate
40 Flushing in Social Anxiety Disorder on Seroquel Completed NCT00773162 Phase 3 Seroquel;Sugar Pill
41 Child and Adolescent Anxiety Disorders (CAMS) Completed NCT00052078 Phase 3 Sertraline (SRT);Placebo
42 Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder Completed NCT00260533 Phase 2, Phase 3 atomoxetine;placebo
43 Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder Completed NCT00074802 Phase 3 Paroxetine
44 Quetiapine in Social Anxiety Disorder Completed NCT00215254 Phase 2, Phase 3 quetiapine
45 Treatment for Anxiety in Children Completed NCT00000389 Phase 3 Fluvoxamine
46 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
47 St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD) Completed NCT00118833 Phase 2, Phase 3 Hypericum perforatum (St. John's wort)
48 Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) Completed NCT02622958 Phase 3 PH94B
49 Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome Completed NCT00114127 Phase 3 Duloxetine;Duloxetine;Placebo
50 A Systems Level Intervention for Unemployed Persons With Social Anxiety Disorder Completed NCT01654510 Phase 2, Phase 3

Search NIH Clinical Center for Phobic Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Phobic Disorder

Anatomical Context for Phobic Disorder

MalaCards organs/tissues related to Phobic Disorder:

39
Brain, Ovary, Skin, Lung, Eye

Publications for Phobic Disorder

Articles related to Phobic Disorder:

(show all 14)
id Title Authors Year
1
Choking Phobia : An Uncommon Phobic Disorder, Treated with Behavior Therapy : A Case Report and Review of the Literature. ( 28638212 )
2016
2
Validation of the diagnoses of panic disorder and phobic disorders in the US National Comorbidity Survey Replication Adolescent (NCS-A) supplement. ( 21495110 )
2011
3
Genetic association between BDNF gene polymorphisms and phobic disorders: a case-control study among mainland Han Chinese. ( 21295349 )
2011
4
The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomized controlled trial. ( 15897725 )
2005
5
Temporal relationship between the age of onset of phobic disorders and development of substance dependence in adolescent psychiatric patients. ( 15283954 )
2004
6
A polymorphic genomic duplication on human chromosome 15 is a susceptibility factor for panic and phobic disorders. ( 11509185 )
2001
7
The longitudinal study of phobic disorder in a community sample from early to late adolescence. ( 11018436 )
2000
8
Social and personal resources and the prevalence of phobic disorder in a community population. ( 10883724 )
2000
9
Phobic disorder, psychotherapy, and risk-taking: an economic perspective. ( 10180917 )
1998
10
Frequency of phobic disorder in a community sample of young adolescents. ( 7559315 )
1995
11
Role of thymic hormones in neuroimmunomodulation. Their use in patients with phobic disorders. ( 1776534 )
1991
12
Administration of thymopentin to patients with phobic disorders improves depressed phagocytic functions. ( 2092042 )
1990
13
Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders. ( 2651489 )
1989
14
Is anorexia nervosa a phobic disorder? A psychophysiological enquiry. ( 7417632 )
1980

Variations for Phobic Disorder

Copy number variations for Phobic Disorder from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 94765 15 70400000 76100000 Copy number LOXL1 phobic disorder

Expression for Phobic Disorder

Search GEO for disease gene expression data for Phobic Disorder.

Pathways for Phobic Disorder

GO Terms for Phobic Disorder

Cellular components related to Phobic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.02 GLRB HTR1A OPRK1 PTK7 SLC6A4

Biological processes related to Phobic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of sensory perception of pain GO:0051930 9.37 COMT OPRK1
2 vasoconstriction GO:0042310 9.32 HTR1A SLC6A4
3 behavior GO:0007610 9.26 HTR1A OPRK1
4 neurotransmitter catabolic process GO:0042135 9.16 COMT MAOA
5 catecholamine metabolic process GO:0006584 8.96 COMT MAOA
6 dopamine catabolic process GO:0042420 8.62 COMT MAOA

Sources for Phobic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....